Healthcare -
Drug Manufacturers - Specialty & Generic - NYSE - US
$ 168.755
0.906 %
$ 75.6 B
Market Cap
30.85
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Zoetis Inc.
| Net Income | 2.5 B |
| Depreciation & Amortization | 497 M |
| Capital Expenditures | -655 M |
| Stock-Based Compensation | 74 M |
| Change in Working Capital | 79 M |
| Others | 294 M |
| Free Cash Flow | 2.3 B |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||
| Net Income | 2 496.0 | 2 344.0 | 2 111.0 | 2 034.0 | 1 636.0 | 1 500.0 | 1 424.0 | 862.0 | 819.0 | 339.0 | 587.0 | 503.0 | 436.0 | 248.0 | 111.0 | (101.0) |
| Depreciation & Amortization | 497.0 | 491.0 | 465.0 | 448.0 | 441.0 | 412.0 | 308.0 | 242.0 | 240.0 | 199.0 | 204.0 | 209.0 | 200.0 | 205.0 | 185.0 | 124.0 |
| Deferred Income Tax | (338.0) | (61.0) | (286.0) | (80.0) | (62.0) | (79.0) | (112.0) | 127.0 | (55.0) | (85.0) | (49.0) | 23.0 | (74.0) | 65.0 | (68.0) | (334.0) |
| Stock Based Compensation | 74.0 | 60.0 | 62.0 | 58.0 | 59.0 | 67.0 | 53.0 | 44.0 | 37.0 | 43.0 | 32.0 | 43.0 | 28.0 | 19.0 | 16.0 | 15.0 |
| Other Operating Activities | 145.0 | 31.0 | 259.0 | 96.0 | 137.0 | 46.0 | 5.0 | 100.0 | 111.0 | 376.0 | 9.0 | 7.0 | 13.0 | 77.0 | (90.0) | 37.0 |
| Change in Working Capital | 79.0 | (512.0) | (699.0) | (343.0) | (85.0) | (151.0) | 112.0 | (29.0) | (439.0) | (208.0) | (157.0) | (104.0) | (149.0) | (117.0) | 100.0 | 357.0 |
| Cash From Operations | 2 953.0 | 2 353.0 | 1 912.0 | 2 213.0 | 2 126.0 | 1 795.0 | 1 790.0 | 1 346.0 | 713.0 | 664.0 | 626.0 | 681.0 | 454.0 | 497.0 | 254.0 | 98.0 |
| INVESTING CASH FLOW | ||||||||||||||||
| Capital Expenditures | (655.0) | (732.0) | (586.0) | (477.0) | (453.0) | (460.0) | (338.0) | (224.0) | (216.0) | (224.0) | (195.0) | (184.0) | (126.0) | (135.0) | (124.0) | (135.0) |
| Other Items | 340.0 | (45.0) | (297.0) | 19.0 | (119.0) | (44.0) | (1 921.0) | (46.0) | 2.0 | (891.0) | 8.0 | 5.0 | (9.0) | (314.0) | 115.0 | (1 686.0) |
| Cash From Investing Activities | (315.0) | (777.0) | (883.0) | (458.0) | (572.0) | (504.0) | (2 259.0) | (270.0) | (214.0) | (1 115.0) | (187.0) | (179.0) | (135.0) | (449.0) | (9.0) | (1 821.0) |
| FINANCING CASH FLOW | ||||||||||||||||
| Common Stock Repurchased | (1 858.0) | (1 092.0) | (1 594.0) | (743.0) | (250.0) | (626.0) | (698.0) | (500.0) | (300.0) | (203.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (3.0) | (1 349.0) | 1 350.0 | (600.0) | 744.0 | (9.0) | 1 504.0 | 481.0 | (405.0) | 1 115.0 | 0 | 2 641.0 | 0 | (143.0) | 0 | 719.0 |
| Dividends Paid | (786.0) | (692.0) | (611.0) | (474.0) | (380.0) | (314.0) | (243.0) | (206.0) | (188.0) | (168.0) | (146.0) | (98.0) | (63.0) | (416.0) | (207.0) | (101.0) |
| Other Financing Activities | (13.0) | 24.0 | (49.0) | (45.0) | 9.0 | (2.0) | (30.0) | (26.0) | (10.0) | 11.0 | (10.0) | (2 743.0) | (15.0) | 529.0 | (70.0) | 1 205.0 |
| Cash From Financing Activities | (2 660.0) | (3 109.0) | (904.0) | (1 862.0) | 123.0 | (951.0) | 533.0 | (251.0) | (903.0) | 755.0 | (154.0) | (200.0) | (78.0) | (30.0) | (277.0) | 1 823.0 |
| CHANGE IN CASH | ||||||||||||||||
| Net Change In Cash | (54.0) | (1 540.0) | 96.0 | (119.0) | 1 670.0 | 332.0 | 38.0 | 837.0 | (427.0) | 272.0 | 272.0 | 293.0 | 238.0 | 16.0 | (36.0) | 93.0 |
| FREE CASH FLOW | ||||||||||||||||
| Free Cash Flow | 2 298.0 | 1 621.0 | 1 326.0 | 1 736.0 | 1 673.0 | 1 335.0 | 1 452.0 | 1 122.0 | 497.0 | 440.0 | 431.0 | 497.0 | 328.0 | 362.0 | 130.0 | (37.0) |